Do not forget the kidney in graves' disease
- PMID: 37093438
- DOI: 10.1007/s11255-023-03600-6
Do not forget the kidney in graves' disease
Abstract
Purpose: To investigate the prevalence of microalbuminuria and factors associated with microalbuminuria in Graves' Disease (GD).
Methods: This cross-sectional and single-center study included 99 patients with GD and 47 healthy controls (HC). Exclusion criteria such as active infection, uncontrolled diabetes, and chronic kidney disease were applied to the participants. The participants' clinical findings, comorbidities, drug use, laboratory tests, and thyroid antibody levels were recorded. Spot urine samples were collected and stored at - 80 ℃ to analyze the presence of microalbuminuria.
Results: The prevalence of microalbuminuria in patients with GD was 12.1%. The median microalbumin/creatinine ratio in spot urine (UACR) in patients with GD (9.49 mg/g [5.09-18.10]) was higher than in the HC group (7.99 mg/g [3.48-12.88], p = 0.033). UACR was correlated with thyroid-stimulating hormone receptor antibody (TRAb), thyroid-stimulating hormone (TSH), and free triiodothyronine (FT3) levels (p = 0.020, p = 0.006, p = 0.009 respectively). In the regression analysis, only the relationship between TRAb level and UACR remained (p = 0.040).
Conclusion: This study demonstrates an increased prevalence of microalbuminuria in patients with GD. There was a significant correlation between microalbuminuria and TRAb level in patients with GD. This relationship suggests that one of the underlying mechanisms of microalbuminuria seen in patients with GD may be autoimmunity.
Keywords: Graves’ disease; Microalbuminuria; Thyroid-stimulating hormone receptor antibody.
© 2023. The Author(s), under exclusive licence to Springer Nature B.V.
Similar articles
-
The association of TSH-receptor antibody with the clinical and laboratory parameters in patients with newly diagnosed Graves' hyperthyroidism: experience from a tertiary referral center including a large number of patients with TSH-receptor antibody-negative patients with Graves' hyperthyroidism.Endokrynol Pol. 2021;72(1):14-21. doi: 10.5603/EP.a2020.0062. Epub 2020 Sep 18. Endokrynol Pol. 2021. PMID: 32944926
-
Clinical significance of thyroglobulin antibodies and thyroid peroxidase antibodies in Graves' disease: a cross-sectional study.Hormones (Athens). 2023 Jun;22(2):253-261. doi: 10.1007/s42000-023-00437-7. Epub 2023 Feb 22. Hormones (Athens). 2023. PMID: 36811756
-
Clinical evaluation of an automated TSI bridge immunoassay in the diagnosis of Graves' disease and its relationship to the degree of hyperthyroidism.BMC Endocr Disord. 2022 Aug 31;22(1):218. doi: 10.1186/s12902-022-01114-3. BMC Endocr Disord. 2022. PMID: 36045442 Free PMC article.
-
Thyroid autoantibodies.J Clin Pathol. 2023 Jan;76(1):19-28. doi: 10.1136/jcp-2022-208290. Epub 2022 Oct 21. J Clin Pathol. 2023. PMID: 36270794 Review.
-
Graves' disease as a driver of depression: a mechanistic insight.Front Endocrinol (Lausanne). 2023 Apr 20;14:1162445. doi: 10.3389/fendo.2023.1162445. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37152963 Free PMC article. Review.
References
-
- Santoro D, Vadalà C, Siligato R, Buemi M, Benvenga S (2017) Autoimmune thyroiditis and glomerulopathies. Front Endocrinol 2(8):119 - DOI
MeSH terms
Substances
LinkOut - more resources
Full Text Sources